Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 14
Submit an article Journal homepage
1,721
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

IgD multiple myeloma: biology, diagnosis, and treatment

Philip A. Egana Ulster University Faculty of Life and Health Sciences, Northern Ireland Centre for Stratified Medicine, Derry, UKView further author information
,
Sheila J. M. O’Connorb St James’s Institute of Oncology, Haematological Malignancy Diagnostic Service, Leeds, UKView further author information
,
W. Ian Deighanc Department of Clinical Chemistry, Altnagelvin Area Hospital, Derry, UKView further author information
,
Conal E. McConvilled Department of Haematology, Altnagelvin Area Hospital, North West Cancer Centre, Derry, UKView further author information
,
Patrick T. Elderd Department of Haematology, Altnagelvin Area Hospital, North West Cancer Centre, Derry, UKView further author information
,
T. C. M. (Curly) Morrise Queen’s University Belfast Faculty of Medicine Health and Life Sciences, Patrick G Johnston Centre for Cancer Research, Belfast, UKView further author information
&
H. Denis Alexandera Ulster University Faculty of Life and Health Sciences, Northern Ireland Centre for Stratified Medicine, Derry, UKCorrespondence[email protected]
View further author information
 show all
Pages 3433-3437 | Received 28 Jan 2022, Accepted 09 Sep 2022, Published online: 20 Oct 2022

References

  • Morris C, Drake M, Apperley J, et al. Efficacy and outcome of autologous transplantation in rare myelomas. Haematologica. 2010;95(12):2126–2133.
  • Lawless S, Sbianchi G, Morris C, et al. IgD subtype but not IgM or non-secretory is a prognostic marker for poor survival following autologous hematopoietic cell transplantation in multiple myeloma. Results from the EBMT CALM (collaboration to collect autologous transplant outcomes in lymphomas and myeloma) study. Clin Lymphoma Myeloma Leuk. 2021;21(10):686–693.
  • Chen L, Fan F, Deng J, et al. Clinical characteristics and prognosis of immunoglobulin D myeloma in the novel agent era. Ann Hematol. 2019;98(4):963–970.
  • Selene II, Jose JA, Khalil MJ, et al. Presentation patterns, diagnostic markers, management strategies, and outcomes of IgD multiple myeloma: a systematic review of literature. Cureus. 2019;11(2):e4011.
  • An G, Xu Y, Shi L, et al. t(11;14) multiple myeloma: a subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome. Leuk Res. 2013;37(10):1251–1257.
  • Sun Q, An G, Liu E, et al. The clinic and pathologic significance of plasma cell myeloma with CCND1. Zhonghua Xue Ye Xue Za Zhi. 2015;36(9):775–779.
  • Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955–2962.
  • Avet-Loiseau H, Garand R, Lode L, et al. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood. 2003;101(4):1570–1571.
  • Lu J, Lu J, Chen W, et al. Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis. Blood Cancer J. 2014;4:e239.
  • Sawyer JR. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet. 2011;204(1):3–12.
  • Gao XY, Ma YP, Chao Y, et al. Clinical characteristics and survival analysis of patients with IgD multiple myeloma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021;29(2):547–552.
  • Smith A, Howell D, Crouch S, et al. Cohort profile: the Haematological Malignancy Research Network (HMRN): a UK population-based patient cohort. Int J Epidemiol. 2018;47(3):700–700g.
  • O'Connor SJM, Turner KR, Barrans SL. Chapter 3: practical applications of fluorescent in situ hybridization techniques in clinical diagnostic laboratories. In: Nielsen B S ' Jones J editors. In situ hybridization protocols. 5th ed., City: Totowa, NJ 07512, USA:Humana Press; 2020
  • Übelhart R, Werner M, Jumaa H. Assembly and function of the precursor B-cell receptor. Curr Top Microbiol Immunol. 2016;393:3–25.
  • Cooper MD. The early history of B cells. Nat Rev Immunol. 2015;15(3):191–197.
  • Gutzeit C, Chen K, Cerutti A. The enigmatic function of IgD: some answers at last. Eur J Immunol. 2018;48(7):1101–1113.
  • Pistofidis R, Ghobrial I. Targeting a myeloma translocation for the first time: the t(11;14) journey. Hematologist. 2018;15(4).
  • Campo E, Cymbalista F, Ghia P, et al. TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. Haematologica. 2018;103(12):1956–1968.
  • Egan PA, Elder PT, Deighan WI, et al. Multiple myeloma with central nervous system relapse. Haematologica. 2020;105(7):1780–1790.
  • Reda G, Cassin R, Dovrtelova G, et al. Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement. Haematologica. 2019;104(5):e222–e223.
  • Jelinek T. Venetoclax: the first anti-myeloma agent with a reliable biomarker. Br J Haematol. 2020;189(6):1003–1005.
  • Basali D, Chakraborty R, Rybicki L, et al. Real-world data on safety and efficacy of venetoclax-based regimens in relapsed/refractory t(11;14) multiple myeloma. Br J Haematol. 2020;189(6):1136–1140.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.